Intervention of Stéphane Delfour at Thai Fact-Checking Network's launch

Stéphane Delfour, AFP Director of the Bangkok bureau, participated Thursday August 24 in the launch of the "Thai Fact-Checking Network", a network of media and organizations committed to the fight against disinformation in Thailand, under the aegis of the Thai Media Fund (TMF), of which AFP is one of the main partners.

AFP journalist wounded in drone attack in east Ukraine

An AFP video journalist was wounded by a drone attack while reporting at a Ukrainian artillery position on Monday, AFP reporters who witnessed the explosion said.


Dylan Collins, a US citizen based in Lebanon but on assignment in Ukraine, sustained multiple shrapnel injuries in the attack in a forested area near Bakhmut.

He was evacuated to a nearby hospital where he was being treated and doctors have said his condition was not life-threatening.

AFP at News Xchange 2023

The 2023 edition of News Xchange, the annual meeting of the international media industry, is currently taking place in Dublin. AFP will take over the emblematic Gravity Bar in Dublin at the Guinness Storehouse on Monday, June 19 from 8 pm for an evening of networking, and will take part in conferences on Tuesday, June 20.

05/28/2025 23:10
Kinaxis Brings AI-Powered Supply Chain Breakthroughs to Tokyo at Kinexions 25

Kinaxis® (TSX: KXS), a global leader in end-to-end supply chain orchestration, today announced it will host Kinexions Japan 25 on Tuesday, June 3, 2025, in Tokyo. This year’s event will spotlight new product capabilities and customer strategies designed for complex, fast-changing supply chain environments. Part of the global Kinexions event series, Kinexions Japan brings together supply chain leaders, business decision-makers, and industry experts to reveal how organizations are accelerating de...

06/03/2025 11:00
Byondis Announces First Patient Dosed in Phase 1 Clinical Trial of Novel SIRPα-Directed Monoclonal Antibody BYON4228 in Patients With Advanced or Metastatic Solid Tumors

Byondis B.V., an independent clinical stage biopharmaceutical company creating innovative targeted medicines for patients with cancer, announces the first patient dosed in its Phase 1 dose escalation and expansion BYON4228.002 clinical trial to evaluate the safety, pharmacokinetics, pharmacodynamics and efficacy of novel SIRPα-directed monoclonal antibody (mAb) BYON4228 alone and in combination with pembrolizumab in patients with advanced or metastatic solid tumors. ...